Advertisement
BIIB vs PFE
Which Stock Would AI Choose? Biogen (BIIB) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Biogen (BIIB) delivered stronger recent performance with a significant Q2 2026 earnings beat and raised full-year guidance, while Pfizer (PFE) trades near 52-week lows ahead of its upcoming earnings.
- BIIB has posted robust year-to-date and one-year returns compared to PFE’s more modest gains, reflecting differing momentum in the biotechnology and pharmaceutical sectors.
- Biogen focuses on neuroscience and specialty therapies with upcoming Phase 3 trials, whereas Pfizer maintains a broad portfolio including vaccines, oncology, and a high dividend yield.
- Market sentiment favors BIIB following recent results, while PFE contends with pipeline execution and loss-of-exclusivity pressures amid stable but lower growth expectations.
- Both companies operate in healthcare but differ in scale, risk profile, and growth drivers, offering distinct trade-offs for investors seeking exposure to biopharma innovation versus established cash flows.
- Relative positioning highlights BIIB’s recent catalysts versus PFE’s emphasis on dividend stability and diversified late-stage pipeline updates.
Introduction
This comparison examines Biogen (BIIB) and Pfizer (PFE) to highlight contrasts in business models, recent financial results, and market positioning within the healthcare sector. The analysis draws on observable performance metrics and developments from recent market activity to assist traders and investors evaluating relative opportunities. It is particularly relevant for those monitoring biotechnology innovation alongside large-cap pharmaceutical stability, dividend income, and sector-wide trends such as clinical trial outcomes and earnings momentum. The discussion emphasizes factual contrasts without forward-looking speculation.
BIIB Overview and Recent Performance
Biogen (BIIB) is a biotechnology company specializing in therapies for neurological and neurodegenerative diseases. In recent market activity, the stock has shown resilience, with shares trading in a range that reflects post-earnings momentum. The company reported second-quarter 2026 revenue of $2.74 billion and adjusted earnings per share of $3.60, both exceeding analyst expectations. Management raised full-year adjusted EPS guidance in response. Year-to-date returns stand at approximately 13-15%, with one-year gains exceeding 50%, outpacing broader market benchmarks. Sentiment has been supported by product performance and upcoming Phase 3 trial timelines, though profitability considerations remain in focus amid a multi-year development cycle.
PFE Overview and Recent Performance
Pfizer (PFE) is a global pharmaceutical company with a diversified portfolio spanning vaccines, oncology, rare diseases, and internal medicine. Recent market activity shows the stock consolidating near the lower end of its 52-week range between roughly $23 and $28.75, with shares around $25. The company maintains a dividend yield near 6.9%. Upcoming second-quarter 2026 earnings are scheduled for early August, with analysts projecting moderated results year-over-year. Pipeline updates include progress in areas such as oncology and dermatology trials. One-year returns approximate 4-5%, reflecting a more measured trajectory compared to peers amid ongoing portfolio transitions and loss-of-exclusivity dynamics.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots drawn from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section. The bots encompass varied trading styles, strategies, timeframes, performance statistics, and ticker universes, allowing users to explore options suited to different risk tolerances and objectives. Factual metrics such as win rates, profit factors, and drawdown ranges are displayed for transparency. For additional details on these automated systems, visit Trending AI Robots.
Head-to-Head Comparison
Biogen (BIIB) operates as a focused biotechnology firm emphasizing neuroscience pipelines, while Pfizer (PFE) functions as a diversified pharmaceutical leader with established revenue streams and a substantial dividend. Growth drivers differ markedly: BIIB benefits from concentrated clinical catalysts and recent earnings outperformance, whereas PFE relies on broad therapeutic areas and recurring income. Recent momentum favors BIIB following its second-quarter results, contrasting with PFE’s steadier but lower-volatility profile near multi-month lows. Risk factors include BIIB’s higher development-stage exposure versus PFE’s scale-related challenges such as patent expirations. Sector exposure places both in healthcare, yet BIIB offers greater sensitivity to innovation cycles and PFE provides defensive characteristics through dividends and global operations. Market sentiment reflects these distinctions, with BIIB showing stronger short-term price resilience tied to fundamental beats.
Tickeron AI Verdict
Based on observable factors including trend consistency, earnings delivery, and relative positioning in recent market activity, Tickeron’s AI models would currently assign higher probabilistic weighting to Biogen (BIIB) over Pfizer (PFE). Stronger recent momentum and a clear earnings catalyst provide a measurable edge in trend and stability metrics, though both equities carry sector-specific variables that warrant ongoing monitoring. This assessment reflects data-driven evaluation rather than definitive outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and PFE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 3 green FA rating(s).
- BIIB’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).
- BIIB’s TA Score: 5 bullish, 1 bearish.
- PFE’s TA Score: 5 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +0.91% price change this week, while PFE (@Pharmaceuticals: Major) price change was +0.11% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.23%. For the same industry, the average monthly price growth was +0.30%, and the average quarterly price growth was +2.34%.
Reported Earning Dates
BIIB is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.23% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BIIB | PFE | BIIB / PFE | |
| Capitalization | 31B | 153B | 20% |
| EBITDA | 2.14B | 17.2B | 12% |
| Gain YTD | 19.228 | 13.144 | 146% |
| P/E Ratio | 37.27 | 35.25 | 106% |
| Revenue | 10B | 63.3B | 16% |
| Total Cash | 1.29B | N/A | - |
| Total Debt | 8.36B | 63.7B | 13% |
BIIB | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 86 | 76 | |
PRICE GROWTH RATING 1..100 | 23 | 29 | |
P/E GROWTH RATING 1..100 | 6 | 7 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (79) in the Biotechnology industry. This means that PFE’s stock grew significantly faster than BIIB’s over the last 12 months.
PFE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.
PFE's SMR Rating (76) in the Pharmaceuticals Major industry is in the same range as BIIB (86) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's Price Growth Rating (23) in the Biotechnology industry is in the same range as PFE (29) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
BIIB's P/E Growth Rating (6) in the Biotechnology industry is in the same range as PFE (7) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
| BIIB | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 65% |
| Stochastic ODDS (%) | 2 days ago 51% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 61% | 2 days ago 50% |
| MACD ODDS (%) | 2 days ago 64% | N/A |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 52% |
| TrendMonth ODDS (%) | 2 days ago 63% | 2 days ago 48% |
| Advances ODDS (%) | 3 days ago 57% | 9 days ago 52% |
| Declines ODDS (%) | 5 days ago 71% | 4 days ago 58% |
| BollingerBands ODDS (%) | N/A | 2 days ago 57% |
| Aroon ODDS (%) | N/A | 2 days ago 45% |
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.04% | ||
| BMY - PFE | 57% Loosely correlated | -1.27% | ||
| MRK - PFE | 55% Loosely correlated | +0.21% | ||
| AMGN - PFE | 53% Loosely correlated | -0.63% | ||
| NVS - PFE | 51% Loosely correlated | -0.55% | ||
| BIIB - PFE | 51% Loosely correlated | -0.39% | ||
More | ||||